John A Kink

This inventor holds 31 USPTO granted patents and 8 published patent applications and 3 EPO patents, primarily in Cancer Therapeutics. Top assignees: Quintessence Biosciences, Inc., Promega Corporation, Wisconsin Alumni Research Foundation. Active years: 1997-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John A Kink. Retrieved from https://idiyas.com/inventor/john-a-kink

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 8)

% Patents Active = 51.6

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 2.8

ph-index = 9

Forward Citations = 324(Granted Patents)

Location History:

Lake Villa, IL (US) (1998)
Madison, WI (US) (1997 - 2023)

Company Filing History:

9 out of 12

Quintessence Biosciences, Inc.

Wisconsin Alumni Research Foundation

patents

4. 5 out of 18

Ophidian Pharmaceuticals, Inc.

patents

5. 1 out of 1

Ochidian Pharmaceuticals, Inc.

patent

6. 1 out of 834,453

Other

patents

Years Active: 1997-2023

Loading Chart...

Areas of Expertise:

Therapeutic Cells

Macrophage Therapy

Ribonucleases

Cancer Treatment

C. Difficile

Antibodies

Inflammatory Bowel Disease

Sepsis

Polyamines

Toxin Neutralization

Autoimmune Disease

Enterocolitis

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11760975 - Generation of therapeutic cells using extracellular components of target organs (2023-09-19),

2. 11738046 - Macrophage cell therapy to treat orthopedic injury (2023-08-29),

3. 11499730 - LPS priming of stromal cells to generate LPS-specific exosome educated macrophages (2022-11-15),

4. 9839638 - Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy (2017-12-12),

5. 9579365 - Therapeutic ribonucleases (2017-02-28),

6. 9192656 - Methods and compositions for the treatment of cancer (2015-11-24),

7. 9006407 - Therapeutic ribonucleases (2015-04-14),

8. 8840882 - Modified ribonucleases (2014-09-23),

9. 8697062 - Compositions and methods for ribonuclease-based therapeutics (2014-04-15),

10. 8628768 - Therapeutic ribonucleases (2014-01-14),

11. 8461136 - Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy (2013-06-11),

12. 8298801 - Methods and compositions for the treatment of cancer (2012-10-30),

13. 8216567 - Therapeutic ribonucleases (2012-07-10),

14. 8029782 - Therapeutic ribonucleases (2011-10-04),

15. 7531562 - Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy (2009-05-12),

Title: John A Kink: Innovator in Cellular Therapy

Introduction: John A Kink is an esteemed inventor based in Madison, WI, known for his significant contributions to the field of cellular therapy. With an impressive portfolio of 30 patents, Kink has made groundbreaking advancements in the generation of therapeutic cells, particularly in applications related to inflammatory diseases and orthopedic injuries.

Latest Patents: Kink's recent patents showcase his innovative approaches. His work titled "Generation of Therapeutic Cells Using Extracellular Components of Target Organs" focuses on an ex vivo generated population of tissue-specific anti-inflammatory macrophages, along with methods for their creation and application. Another notable patent, "Macrophage Cell Therapy to Treat Orthopedic Injury," details a method for generating alternatively-activated macrophages aimed at treating orthopedic injuries, highlighting the potential of these cells in regenerative medicine.

Career Highlights: John A Kink has collaborated with prominent companies in the biotech field, including Quintessence Biosciences, Inc. and Promega Corporation. His expertise and contributions have advanced the development of novel therapies that leverage the body's own cellular mechanisms for healing and recovery.

Collaborations: Throughout his career, Kink has worked alongside notable colleagues such as Laura Strong and Douglas C Stafford. These collaborations have enriched his research and development efforts, leading to innovative solutions in the life sciences sector.

Conclusion: John A Kink's contributions to cellular therapy and his extensive patent portfolio reflect his dedication to innovation in the medical field. His work not only enhances our understanding of macrophage biology but also opens new pathways for treating various ailments, positioning him as a key figure in contemporary biomedical research.

Profile summary based on public USPTO records.